Dirlotapide
From Wikipedia, the free encyclopedia
 |
|
|
Dirlotapide
|
|
| Systematic (IUPAC) name | |
| 1-Methyl-N-[(1S)-2-(methyl-(phenylmethyl)amino)-2-oxo-1-phenylethyl]-5-[ [oxo-[2-[4-(trifluoromethyl)phenyl]phenyl]methyl]amino]-2-indolecarboxamide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C40H33F3N4O3 |
| Mol. mass | 674.71 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Dirlotapide is a drug used to treat obesity in dogs. It is manufactured by Pfizer and marketed as Slentrol.
It works as a selective microsomal triglyceride transfer protein inhibitor. This blocks the assembly and release of lipoproteins into the bloodstream, thereby reducing fat absorption. It also elicits a satiety signal from lipid-filled cells lining the intestine.
It is supplied as an oral solution. It is not intended for use in humans or cats or parrots.
On January 5 2007, the FDA approved Slentrol, the first time the FDA has approved a drug for obese dogs.[1]
[edit] References
- ^ FDA approves 1st drug for obese dogs. Yahoo. Retrieved on 2007-01-06.[dead link]
[edit] External links
 |
This veterinary medicine related article is a stub. You can help by expanding it. |
